Recent Updates
Recently added Catalysts
MAZE Neutral Sentiment

After deal about-face and a spinout, Maze assembles $115M Series D

Key Takeaway: Maze Therapeutics has successfully raised $115 million in a Series D funding round following a strategic deal reversal and a spinout. This funding aims to support the company's ongoing research and development efforts. The financial backing reflects investor confidence in Maze's potential despite recent organizational changes.

Market Sentiment Analysis

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+9%
120-day peak, hindsight
Typical move
1.8%
average across 3 past catalysts
Cash runway
~31 mo
Minimal dilution risk
Lead asset
MZE829
Phase 2 · Proteinuric Kidney Disease

Full Press Release Details

• Privacy Overview
• Essential Cookies
• 3rd Party Cookies
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
These cookies are necessary for our website to function and for measurement purposes. Opt-out rights do not apply to these cookies.
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.
Last updated: Dec 3, 2024